|
"Renoprotective effect of the
angiotensin-receptor antagonist irbesartan in patients with nephropathy
due to type 2 diabetes," by
Edmund J. Lewis and 9 others, New England Journal of Medicine, 345(12):
851-60, 20 September 2001.
Abstract: "Background It is unknown whether either the
angiotensin-II-receptor blocker irbesartan or the
calcium-channel blocker amlodipine slows the progression of nephropathy in
patients with type 2 diabetes independently of its capacity to lower the
systemic blood pressure. Methods We randomly assigned 1715 hypertensive
patients with nephropathy due to type 2 diabetes to treatment with irbesartan
(300 mg daily), amlodipine (10 mg daily), or placebo. The target blood
pressure was 135/85 mm Hg or less in all groups. We compared the groups with
regard to the time to the primary composite end point of a doubling of the
base-line serum creatinine concentration, the development of end-stage renal
disease, or death from any cause. We also compared them with regard to the
time to a secondary cardiovascular composite end point. Results The
mean duration of follow-up was 2.6 years. Treatment with irbesartan was
associated with a risk of the primary composite end point that was 20 percent
lower than that in the placebo group (P=0.02) and 23 percent lower than that
in the amlodipine group (P=0.006). The risk of a doubling of the serum
concentration was 33 percent lower in the irbesartan group than in the placebo
group (P=0.003) and 37 percent lower in the irbesartan group than in the
amlodipine group (P<0.001). Treatment with irbesartan was associated with a
relative risk of end-stage renal disease that was 23 percent lower than that
in both other groups (P=0.07 for both comparisons). These differences were not
explained by differences in the blood pressures that were achieved. The serum
creatinine concentration increased 24 percent more slowly in the irbesartan
group than in the placebo group (P=0.008) and 21 percent more slowly than in
the amlodipine group (P=0.02). There were no significant differences in the
rates of death from any cause or in the cardiovascular composite end point. Conclusions
The angiotensin-II receptor blocker irbesartan is effective in protecting
against the progression of nephropathy due to type 2 diabetes. This protection
is independent of the reduction in blood pressure it causes."
This 2001 report from the New England
Journal of Medicine was cited 62 times in current journal
articles
indexed in the Thomson ISI database during July-August 2003. During that
two-month period, this was the
third-most-cited paper in medicine, aside from reviews, published in the last
two years. Prior to the most recent
bimonthly count, citations to the paper have accrued as follows:
May-June 2003: 41 citations
March-April 2003: 53
January-February 2003: 47
November-December 2002: 57
September-October 2002: 38
July-August 2002: 29
May-June 2002: 27
March-April 2002: 20
January-February 2002: 16
November-December 2001: 8
September-October 2001: 4
Total citations to date: 402
SOURCE: Hot
Papers Database (Included with a subscription to the ISI print newsletter Science
Watch®, available from the ISI
Research Services Group. Packaged on a CD-ROM that is mailed with each Science
Watch issue, the Hot
Papers Database contains data on hundreds of highly cited papers published
during the last two years. User interface permits searching by author,
organization, journal, field, and more. Total citations, as well as citations
accrued during successive bimonthly periods, can be assessed and graphed. An
updated CD containing the most recent bimonthly data is mailed with every new
issue of Science
Watch,
six times a year. The CD also includes an electronic version of the Science
Watch
issue in HTML format, for personal desktop access.)
Previous Page | Return to SCI-BYTES
Main Menu
| Return to 2003 Menu
If you came from the Thomson Scientific Web site, click
here to return
|
cites
:
